MedPath

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

Completed
Conditions
Pneumonia, Pneumocystis Carinii
HIV Infections
Registration Number
NCT00000908
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP.

The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which fight infection) are more than 200 cells/mm3. This study looks at whether it is acceptable to stop PCP prevention treatment in these patients.

Detailed Description

The risk of developing PCP may be decreased with treatment-induced recovery of CD4 counts to \> 200 cells/mm3. Few data exist to confirm or negate the continued necessity of PCP prophylaxis for such patients. This study will assess the effects of discontinuing therapy.

Subjects are asked to discontinue PCP prophylaxis if antiretroviral therapy has resulted in a sustained CD4 increase greater than 200 cells/mm3 on two measurements at least 12 weeks apart. They will be evaluated for symptoms and CD4 counts every 8 weeks as well as plasma for HIV-RNA every 16 weeks for 18 months. Subjects whose CD4 count falls to less than 150 cells/mm3 or between 150 and 200 cells/mm3 will have the CD4 count re-evaluated immediately or within 4 weeks. If the second CD4 count is less than 200 cells/mm3 for either case, conventional PCP prophylaxis will be resumed and the subject will be followed on study. Subjects will be followed during study by physical exams and laboratory tests at Weeks 4, 8, and every 8 weeks thereafter.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (54)

Univ of Alabama at Birmingham

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Kaiser Foundation Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Harbor City, California, United States

Kaiser Permanente LAMC

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Univ of Southern California / LA County USC Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Willow Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Menlo Park, California, United States

Univ of California / San Diego Treatment Ctr

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

San Francisco AIDS Clinic / San Francisco Gen Hosp

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

San Francisco Gen Hosp

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium

๐Ÿ‡บ๐Ÿ‡ธ

San Jose, California, United States

Marin County Specialty Clinic

๐Ÿ‡บ๐Ÿ‡ธ

San Rafael, California, United States

Scroll for more (44 remaining)
Univ of Alabama at Birmingham
๐Ÿ‡บ๐Ÿ‡ธBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.